Literature DB >> 11063672

Evaluation of the needs of male carriers of mutations in BRCA1 or BRCA2 who have undergone genetic counseling.

A Liede1, K Metcalfe, D Hanna, E Hoodfar, C Snyder, C Durham, H T Lynch, S A Narod.   

Abstract

To date, the concerns of men at risk of inheriting a BRCA1 mutation or a BRCA2 mutation have received little attention. It had been anticipated that few men would be interested in predictive testing when a BRCA mutation was identified in their family. However, these men are often affected emotionally by diagnoses of breast cancer in their relatives and may themselves harbor fears that cancer will develop. Male carriers of BRCA1/2 mutations are at increased risk of development of cancers of several types, including those of the breast and prostate. We conducted an evaluation of the needs and experiences of 59 male carriers of BRCA1/2 mutations followed at either the University of Toronto or Creighton University. We assessed their motivations for seeking genetic counseling and testing, involvement in family discussions of breast and ovarian cancer, risk perception, changes in cancer-screening practices, and overall satisfaction with the genetic-counseling process. The principal motivation for seeking genetic counseling was concern for their daughters. The majority (88%) of men participated in family conversations about breast and ovarian cancer, and 47% participated in conversations about prophylactic surgery. Most men believed that they were at increased risk of development of cancer (prostate, breast, colorectal, and skin cancers). However, fewer than one-half (43%) of the men with no previous diagnosis of cancer stated that their prostate cancer-surveillance practices had changed after they had received genetic test results. More than one-half (55%) had intrusive thoughts about their cancer risk. Although levels of satisfaction were high, practitioners should be aware of (a) potential pressures influencing men to request predictive testing, (b) the difficulties that men encounter in establishing surveillance regimens for breast and prostate cancer, and (c) the general lack of information about men's particular experiences in the medical community.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11063672      PMCID: PMC1287926          DOI: 10.1086/316907

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  33 in total

1.  Counseling families with hereditary breast and ovarian cancer: A psychosocial perspective.

Authors:  M P Richards; N Hallowell; J M Green; F Murton; H Statham
Journal:  J Genet Couns       Date:  1995-09       Impact factor: 2.537

2.  A descriptive study of BRCA1 testing and reactions to disclosure of test results.

Authors:  H T Lynch; S J Lemon; C Durham; S T Tinley; C Connolly; J F Lynch; J Surdam; E Orinion; S Slominski-Caster; P Watson; C Lerman; P Tonin; G Lenoir; O Serova; S Narod
Journal:  Cancer       Date:  1997-06-01       Impact factor: 6.860

3.  Common mutations in BRCA1 and BRCA2 do not contribute to early prostate cancer in Jewish men.

Authors:  K L Nastiuk; M Mansukhani; M B Terry; P Kularatne; M A Rubin; J Melamed; M D Gammon; M Ittmann; J J Krolewski
Journal:  Prostate       Date:  1999-08-01       Impact factor: 4.104

4.  Assessment and counseling for women with a family history of breast cancer. A guide for clinicians.

Authors:  K F Hoskins; J E Stopfer; K A Calzone; S D Merajver; T R Rebbeck; J E Garber; B L Weber
Journal:  JAMA       Date:  1995-02-15       Impact factor: 56.272

5.  Men in breast cancer families: a preliminary qualitative study of awareness and experience.

Authors:  M F McAllister; D G Evans; W Ormiston; P Daly
Journal:  J Med Genet       Date:  1998-09       Impact factor: 6.318

6.  Prophylactic surgery decisions and surveillance practices one year following BRCA1/2 testing.

Authors:  C Lerman; C Hughes; R T Croyle; D Main; C Durham; C Snyder; A Bonney; J F Lynch; S A Narod; H T Lynch
Journal:  Prev Med       Date:  2000-07       Impact factor: 4.018

Review 7.  Distress in individuals facing predictive DNA testing for autosomal dominant late-onset disorders: comparing questionnaire results with in-depth interviews. Rotterdam/Leiden Genetics Workgroup.

Authors:  A C DudokdeWit; A Tibben; H J Duivenvoorden; M F Niermeijer; J Passchier; R W Trijsburg
Journal:  Am J Med Genet       Date:  1998-01-06

8.  Controlled trial of pretest education approaches to enhance informed decision-making for BRCA1 gene testing.

Authors:  C Lerman; B Biesecker; J L Benkendorf; J Kerner; A Gomez-Caminero; C Hughes; M M Reed
Journal:  J Natl Cancer Inst       Date:  1997-01-15       Impact factor: 13.506

9.  Genetic counseling for families with inherited susceptibility to breast and ovarian cancer.

Authors:  B B Biesecker; M Boehnke; K Calzone; D S Markel; J E Garber; F S Collins; B L Weber
Journal:  JAMA       Date:  1993-04-21       Impact factor: 56.272

10.  Informational needs of individuals and families with hereditary cancers.

Authors:  P T Kelly
Journal:  Semin Oncol Nurs       Date:  1992-11       Impact factor: 2.315

View more
  32 in total

1.  Stigmatization and male identity: Norwegian males' experience after identification as BRCA1/2 mutation carriers.

Authors:  Nina Strømsvik; Målfrid Råheim; Nina Oyen; Lars Fredrik Engebretsen; Eva Gjengedal
Journal:  J Genet Couns       Date:  2010-03-20       Impact factor: 2.537

2.  The Quality of Genetic Counseling and Connected Factors as Evaluated by Male BRCA1/2 Mutation Carriers in Finland.

Authors:  Outi Kajula; Maria Kääriäinen; Jukka S Moilanen; Helvi Kyngäs
Journal:  J Genet Couns       Date:  2015-09-29       Impact factor: 2.537

3.  Predictive Genetic Testing and Alternatives to Face to Face Results Disclosure: A Retrospective Review of Patients Preference for Alternative Modes of BRCA 1 and 2 Results Disclosure in the Republic of Ireland.

Authors:  Rosie O'Shea; Marie Meany; Cliona Carroll; Nuala Cody; David Healy; Andrew Green; Sally Ann Lynch
Journal:  J Genet Couns       Date:  2015-09-26       Impact factor: 2.537

Review 4.  How risk is perceived, constructed and interpreted by clients in clinical genetics, and the effects on decision making: systematic review.

Authors:  Stephanie Sivell; Glyn Elwyn; Clara L Gaff; Angus J Clarke; Rachel Iredale; Chris Shaw; Joanna Dundon; Hazel Thornton; Adrian Edwards
Journal:  J Genet Couns       Date:  2007-10-30       Impact factor: 2.537

5.  Results of an intervention for individuals and families with BRCA mutations: a model for providing medical updates and psychosocial support following genetic testing.

Authors:  Wendy McKinnon; Shelly Naud; Taka Ashikaga; Rose Colletti; Marie Wood
Journal:  J Genet Couns       Date:  2007-06-27       Impact factor: 2.537

6.  "Second-Class Status?" Insight into Communication Patterns and Common Concerns Among Men with Hereditary Breast and Ovarian Cancer Syndrome.

Authors:  Alexandra Suttman; Robert Pilarski; Doreen M Agnese; Leigha Senter
Journal:  J Genet Couns       Date:  2018-02-05       Impact factor: 2.537

7.  Family Communication in Inherited Cardiovascular Conditions in Ireland.

Authors:  Sinead Whyte; Andrew Green; Marion McAllister; Hannah Shipman
Journal:  J Genet Couns       Date:  2016-06-08       Impact factor: 2.537

8.  Unpacking the blockers: understanding perceptions and social constraints of health communication in hereditary breast ovarian cancer (HBOC) susceptibility families.

Authors:  June A Peters; Regina Kenen; Lindsey M Hoskins; Laura M Koehly; Barry Graubard; Jennifer T Loud; Mark H Greene
Journal:  J Genet Couns       Date:  2011-05-06       Impact factor: 2.537

9.  Disclosure of genetics research results after the death of the patient participant: a qualitative study of the impact on relatives.

Authors:  E Ormondroyd; C Moynihan; M Watson; C Foster; S Davolls; A Ardern-Jones; R Eeles
Journal:  J Genet Couns       Date:  2007-05-11       Impact factor: 2.537

10.  Prostate screening uptake in Australian BRCA1 and BRCA2 carriers.

Authors:  Joanne M McKinley; Prue C Weideman; Mark A Jenkins; Michael L Friedlander; John L Hopper; Sue-Anne McLachlan; Geoffrey J Lindeman; Kelly-Anne Phillips
Journal:  Hered Cancer Clin Pract       Date:  2007-09-15       Impact factor: 2.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.